Increases in administration and corporate costs are probably due to the acquisition of the lease that was included as part of the azer-cel licensing agreement.
From that earlier announcement on azer-cel licensing.
"Imugene will also acquire the lease to a state-of-the art 32,800 sq feet GMP manufacturing facility in North Carolina, drug material for completion of a Phase 1b clinical trial and a highly experienced cell therapy and manufacturing team of approximately 50 personnel."
The above is also confirmed in the 4C with the following:
"Imugene's azer-cel clinical drug is supplied from the company’s state-of-the-art manufacturing facility in North Carolina."
The current 4C probably reflects the full effects of the costs of acquiring that lease.
Given that Azer-cel was acquired in late August, the prior 4C only partially reflected the running costs of this facility.
- Forums
- ASX - By Stock
- IMU
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-18
-
-
- There are more pages in this discussion • 99 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $382.1M |
Open | High | Low | Value | Volume |
5.3¢ | 5.4¢ | 5.2¢ | $216.1K | 4.106M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
31 | 1854997 | 5.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.3¢ | 382882 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
27 | 1694499 | 0.052 |
37 | 4870470 | 0.051 |
51 | 4160179 | 0.050 |
17 | 2263068 | 0.049 |
19 | 954663 | 0.048 |
Price($) | Vol. | No. |
---|---|---|
0.053 | 282882 | 3 |
0.054 | 2751851 | 4 |
0.055 | 1611272 | 15 |
0.056 | 2792035 | 11 |
0.057 | 700330 | 7 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |